Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection.
We have previously demonstrated an impact of the BRAF inhibitor vemurafenib on patient lymphocyte counts. In the current study, the extent to which concomitant use of corticosteroids in BRAF inhibitor treated patients affects lymphocyte counts and predisposes to infection was investigated. A cohort...
Main Authors: | Wiebke Sondermann, Klaus G Griewank, Bastian Schilling, Elisabeth Livingstone, Julia C Leyh, Natalia Rompoti, Ioana Cosgarea, Tobias Schimming, Dirk Schadendorf, Lisa Zimmer, Uwe Hillen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4405567?pdf=render |
Similar Items
-
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
by: Tiziana Notarangelo, et al.
Published: (2017-10-01) -
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
by: Klaus G Griewank, et al.
Published: (2013-01-01) -
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells
by: Luca Mologni, et al.
Published: (2018-05-01) -
BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
by: Francesca Del Bufalo, et al.
Published: (2018-11-01) -
Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
by: Morgane Broudic-Guibert, et al.
Published: (2019-07-01)